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Abstract
Tumor oxygenation has long been recognized as a
significant factor influencing cancer therapy. We
recently established a novel magnetic resonance in
vivo approach to measuring regional tumor oxygen
tension, FREDOM (Fluorocarbon Relaxometry Using
Echo Planar Imaging for Dynamic Oxygen Mapping),
using hexafluorobenzene (HFB) as the reporter
molecule. We have now investigated oxygen dynam-
ics in the two Dunning prostate R3327 rat tumor
sublines, AT1 and H. FREDOM revealed considerable
intratumoral heterogeneity in the distribution of
pO2 values in both sublines. The anaplastic faster-
growing AT1 tumors were more hypoxic compared
with the size-matched, well-differentiated, and slow-
er-growing H tumors. Respiratory challenge with
oxygen produced significant increases in mean and
median pO2 in all the H tumors (P<.001), but no
response in half of the larger AT1 tumors (>3 cm3).
Immunohistochemical studies using the hypoxia
marker, pimonidazole, and the vascular endothelial
cell marker, CD31, confirmed that the H tumors had
more extensive vasculature and less hypoxia than
the AT1 tumors. These results further validate the
utilization of FREDOM to monitor tumor oxygenation
and concur with the hypothesis that the level of
hypoxia is related to tumor growth rate and poor
vascularity.
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Introduction
It is well recognized that hypoxia in solid tumors affects
response to radiotherapy [1–3] and some chemotherapeu-
tic drugs [4]. Recent evidence, in experimental and clinical
studies, indicates that tumor hypoxia might also be a
mechanism for malignant progression and metastasis in
solid tumors [5,6]. Given the importance of oxygen, many
techniques for monitoring pO2 have been developed [7].
Although each method has specific attributes, many are
highly invasive and impractical for longitudinal studies of
specific regions of interest.
We recently demonstrated the feasibility of measuring
tumor oxygenation based on 19F nuclear magnetic resonance
(NMR) echo planar imaging (EPI) following direct intratumoral
injection of the reporter molecule, hexafluorobenzene
(HFB)—FREDOM (Fluorocarbon Relaxometry Using Echo
Planar Imaging for Dynamic Oxygen Mapping) [8]. This
technique allows us to not only simultaneously examine multi-
ple specific locations within a tumor, but also observe
dynamic changes at individual locations with respect to inter-
vention. Our previous studies of Dunning R3327 prostate rat
tumor sublines have demonstrated that the faster-growing
metastatic MAT-Lu tumors were more hypoxic than the
relatively well-differentiated and slower-growing HI tumors
[9]. In order to further investigate the potential correlation
between hypoxia and tumor malignant progression, we have
now studied and compared tumor oxygen tension dynamics
in two other Dunning prostate rat tumor sublines: the well-
differentiated and slower-growing H and the anaplastic fast-
growing AT1, which derives originally from the course of
passage of the H [10].
There is a close relationship between hypoxia and vas-
cular extent in solid tumors, and it is widely accepted that
tumor hypoxia results in part from poor vascularity [11].
Immunohistochemistry based on bioreductive chemical
markers and vascular endothelial cell markers can reveal
spatial patterns of tumor hypoxia and vasculature, as well as
their relationship at the cellular level [12–14]. We have now
compared direct pO2 measurements using FREDOM with
histological investigations of hypoxia and vasculature using
pimonidazole and anti-CD31 antibody, and show that the
macroscopic dynamic imaging is consistent with the histo-
logical microstructure.
Abbreviations: EPI, echo planar imaging; FREDOM, Fluorocarbon Relaxometry Using Echo
Planar Imaging for Dynamic Oxygen Mapping; HF, hypoxic fraction; HFB, hexafluorobenzene;
VDT, volume doubling time
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Methods
Experiments were approved by the Institutional Animal Care
and Research Advisory Committee.
Tumor Model
Two sublines of the Dunning prostate R3327 adenocar-
cinoma were selected: H, a well-differentiated and slow-
growing tumor with volume doubling time (VDT) of 16 days
[15], and AT1, an anaplastic and faster-growing subline with
VDT of 5 days [10]. Tumors were originally obtained from
Dr. J. T. Isaacs (Johns Hopkins, Baltimore, MD) and
provided to us by Dr. P. Peschke (DKFZ, Heidelberg,
Germany). Tumorswere implanted in a skin pedicle surgically
created on the foreback of adult male Copenhagen-2331 rats
(f250 g; Harlan, Indianapolis, IN), as described in detail
previously [16]. Tumorswere allowed to growandwere inves-
tigated by magnetic resonance imaging (MRI) when about
1 cm3 or when >3 cm3 (f10 mm or >20 mm in diameter).
TwelveH tumors, including six small (size range0.6–1.5 cm3)
andsix large tumors (range3.0–4.6cm3), and13AT1 tumors,
including seven small (range 0.7–1.8 cm3) and six large
tumors (range3.0–5.2cm3),were investigated. Inpreparation
for MRI, each rat was given ketamine hydrochloride (200 Al,
100 mg/ml, i.p.; Aveco, Fort Dodge, IA) as a relaxant and
maintained under general gaseous anesthesia (1 dm3/min air
and 1.3% isoflurane; Baxter International, Deerfield, IL). HFB
(50 Al; Lancaster, Gainesville, FL) was deoxygenated by
bubbling nitrogen for 5 minutes before use, and injected
directly into the tumors using a Hamilton syringe (Hamilton,
Reno, NV) with a custom-made fine sharp needle (32 gauge),
as described in detail previously [9]. Generally, HFB was
administered along three tracks in the form of a fan in a single
central planeof the tumor coronal to the rat’s body.Theneedle
was inserted manually to penetrate across the whole tumor
and withdrawnf1 mm to reduce pressure, and 3 Al of HFB
was deposited. The needle was repeatedly withdrawn a
Figure 1. pO2 maps obtained using FREDOM. Distinct heterogeneity was seen in these representative small H (1.1 cm
3) and AT1 (1.5 cm3) tumors under baseline
conditions, when the anesthesized rats breathed air. The H tumor [baseline mean pO2=20.3F2.2 (SE) Torr] was significantly better oxygenated than the AT1
tumor (baseline mean pO2=5.3F0.9 Torr, P<.001). In response to oxygen inhalation, pO2 increased significantly in both the H and the AT1 tumors [mean
pO2=46.7F3.7 Torr (P<.001) and 17.2F3.8 Torr (P<.005), respectively]. In each case, the fourth measurement after switching to oxygen breathing is shown.
Colored voxels were selected by applying threshold criteria to each ensuring high-quality data throughout the time course. Gray voxels provided a T1 curve fit, but
with large errors.
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further2 to3mmandadditionalHFBwasdeposited.Typically,
HFB was deliberately deposited at about 16 individual loca-
tionsper tumor, inboth thecentralandperipheral regionsof the
tumors, to ensure that the interrogated regions would be
representative of the whole tumor. Each animal was placed
on its side in a cradle with a thermal blanket to maintain body
temperature.
Tumor Oximetry—FREDOM
Magnetic resonance experiments were performed using
an Omega CSI 4.7 horizontal bore magnet system with
actively shielded gradients (Bruker Instrument, Fremont,
CA). A tunable (1H/19F) MR coil, 2 or 3 cm in diameter
matched to the tumor size (constructed from a cylindrical
copper tube about 2 cm deep and acting as a single-turn
solenoid), was placed around the tumor-bearing pedicle.
Proton images were obtained for anatomical reference using
a three-dimensional (3D) spin-echo sequence. The coil was
then retuned in place to 188.27 MHz, and corresponding
[19F]MR images were obtained. Overlaying the [19F]MR
images on the corresponding proton images revealed the
distribution of HFB.
Following conventional MR imaging, tumor oxygenation
was estimated on the basis of 19F pulse burst saturation
recovery (PBSR) EPI relaxometry of the HFB, as described
previously [8]. The ARDVARC (Alternated R1 Delays with
Variable Acquisitions to Reduce Clearance effects) data
acquisition protocol was applied to optimize data quality. This
approach provided pO2 maps with 1.25 mm in-plane voxel
resolution in 8 minutes with typically f50 to 150 individual
pO2 measurements (voxels per tumor). The spin– lattice
relaxation rate [R1 (sec1)=1/T1] was estimated on a voxel-
by-voxel basis using a three-parameter monoexponential
function, and pO2 was estimated using the relationship pO2
(Torr)=(R10.0835)/0.001876 [8]. Three consecutive base-
line pO2measurements weremade over 24minutes while the
rats breathed air. The inhaled gas was then altered to oxygen
(100%O2) and pO2 maps were immediately acquired with no
equilibration period. Five consecutive maps were acquired
over 40 minutes. The gas was then returned to air, and five
further maps were acquired over 40 minutes.
Histology
Histological studies were performed on large AT1 and
H tumors.
Necrosis
For H&E staining, tumor tissues were fixed in 10%
formalin, embedded in paraffin, and sectioned (4 Am). Tumor
necrotic regions were identified on the H&E stained slides
examined under low magnification (2 objective). All fields
(f30) in each section were captured by a digital camera and
Figure 2. Histograms of tumor oxygenation pooled for the H tumors. Data from six small (219 voxels) and six large (159 voxels) H tumors obtained using FREDOM
show distinct heterogeneity. The small tumors (A) were significantly better oxygenated (mean=31F2 Torr, median=27 Torr) than the large tumors (B) (mean=14F1
Torr, median=12 Torr; P<.001). In response to respiratory challenge with oxygen, both mean andmedian pO2 in each group increased significantly (P<.001). Arrows
indicate mean (x) and median (m) pO2, respectively. The bin numbers show the maximum pO2 for each category. Cumulative frequencies are shown by curves.
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processed using Metaview software (Universal Imaging,
West Chester, PA). Fields were calibrated according to
magnification, and areas occupied by necrotic cells were
outlined, calculated, and expressed in square millimeters.
The area of the entire cross section was determined man-
ually. The proportion of necrotic areas (% necrosis) was
calculated as follows: sum of all necrotic areas in a single
cross section divided by total area of cross section and
multiplied by 100. Five slides representing each tumor type
were analyzed and the percentage of necrosis was calcu-
lated and averaged for each tumor.
Immunohistochemical Detection of Hypoxia
Pimonidazole hydrochloride (Hypoxyprobe-1; NPI, Bel-
mont, MA) was injected into the tail vein at a dose of 60 mg/
kg. Ninety minutes later, rats were anesthesized and then
perfused for 20 minutes with physiological saline containing
5 mM CaCl2. For immunohistochemistry, the tissues were
immediately immersed in liquid nitrogen and stored at
80jC. After cryostat sectioning (6 Am thick), tumor sections
were fixed in acetone for 5 minutes and then rehydrated in
phosphate-buffered saline containing 0.1% Tween-20
(PBST) for 10 minutes. Monoclonal antibody Mab1 (NPI)
that detects pimonidazole–protein adducts was diluted
1:100 and added to frozen sections followed by incubation
for 2 hours at 37jC. Slides were then incubated for 1 hour at
37jC with horseradish peroxidase (HRP)–conjugated goat
antimouse secondary antibody (1: 100 dilution; Serotec,
Raleigh, NC). After a PBST wash, sections were immersed
in AEC substrate (3-amino-9-ethylcarbazole; Vector Labo-
ratories, Burlingame, CA) for 15 minutes at room temper-
ature. Finally, sections were counterstained with hematoxylin
and observed under light microscopy. Hypoxic fraction was
determined as area positively stained for pimonidazole rela-
tive to the total tissue area using Metaview software.
Blood Vessel Density
Mouse antirat CD31 monoclonal antibody (1:20; Serotec)
and HRP-conjugated goat antimouse secondary antibody
(1:100) were used to detect tumor blood vessels on 6-Am
sections immediately adjacent to those used for detection of
hypoxia. Vascular density was evaluated using the ‘‘hot spot’’
technique described by Weidner [17]. The five most vascu-
larized areas in each tumor were selected under low magni-
fication (4). Vascular density was determined by counting
the total number of structures positive for CD31 using 10
objective (area 0.318 mm2) and calculating the mean num-
ber of vessels per square millimeter.
Figure 3. Histograms of tumor oxygenation pooled for the AT1 tumors. Seven small tumors (A) (280 voxels) showed significantly higher baseline pO2 (mean=14F1
Torr, median=11 Torr) than the six large tumors (B) (149 voxels; mean=4F1 Torr, median=3 Torr; P<0.001). With respect to oxygen challenge, mean pO2 in both
groups increased significantly (P<.001). However, the median pO2 in the large tumors only increased from 3 to 8 Torr. Comparison with the H tumors (Figure 2)
showed that both groups of small and large AT1 tumors were less well oxygenated (P<.001). Arrows indicate mean (x) and median (m) pO2, respectively.
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Statistical Analysis
The statistical significance of changes in oxygenation was
assessed using analysis of variance (ANOVA) on the basis
of Fisher’s Protected Least Significant Difference (PLSD)
(Statview; SAS Institute, Cary, NC). Where appropriate, the
Student’s t-test was applied. Hypoxic fractions (HF2.5,5,10
<2.5, 5, 10 Torr) measured by FREDOM in all the tumors
were calculated from the fraction of hypoxic voxels in each
pO2 map. All data are quoted FSE.
Results
Tumor Oximetry—FREDOM
Overlay of 19F on 1H images (not shown) confirmed that
HFB was widely distributed, predominantly in a central slice,
and occupied voxels representing 5% to 10% of the whole
tumor. In the series of EPI relaxation data sets, typicallyf50
to 300 voxels provided an R1 fit and potential pO2 value.
Because even noise may give an apparent relaxation curve
Figure 4. Dynamic oxygenation at individual locations with initial pO2<10 Torr (hypoxic) in response to oxygen breathing. (a) A total of 92 initially hypoxic voxels
from both the small (n=31) and the large (n=61) H tumors, and 248 hypoxic voxels from the small (n=131) and large AT1 (n=117) tumors were followed with respect
to gas challenge. The mean pO2 in each subline increased immediately after oxygen breathing, and reached a mean pO2=55F5 (SE) Torr in H versus 18F2 Torr
in AT1, respectively (P<.001) after 40 minutes. (b) Dynamic hypoxic fraction (HF10<10 Torr) in the initially hypoxic regions of the H tumors decreased to a minimum
<10%, 24 minutes after switching to oxygen inhalation, whereas >60% initially hypoxic regions remained in the AT1 tumors (*P<.001).
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(R1) fit, data were selected within a region of interest, having
T1 error <2.5 seconds and ratio T1 error/T1 <50%. With
respect to respiratory interventions, only those voxels that
provided consistently reliable data during the time course
were included for further analysis. The number of such
acceptable voxels ranged from 11 to 74 per tumor. Figure 1
shows typical pO2 maps of the selected regions obtained
from representative small H and AT1 tumors under baseline
air breathing and during oxygen challenge. During air breath-
ing, both tumors exhibited extensive heterogeneity in pO2
distribution, but the H tumor was better oxygenated than the
AT1 tumor (P<.001). Upon switching to oxygen breathing,
both tumors responded with significantly increased mean
pO2 (P<.001).
Data for small and large tumors in the H and AT1 sublines
are pooled as histograms in Figures 2 and 3, respectively.
For the H tumors (Figure 2), a total of 219 voxels from the six
small H tumors were pooled and gave a mean baseline
pO2=31F2 Torr (median=27 Torr), which was significantly
greater (P<.001) than for the six larger H tumors (159
voxels), which had a value of 14F1 Torr (median=12 Torr).
For the AT1 subline (Figure 3), the seven small tumors (280
voxels) had a mean pO2 of 14F1 Torr (median=11 Torr),
which was significantly greater (P<.001) compared to the six
large AT1 tumors (149 voxels; mean=4F1 Torr, median=3
Torr). Comparison of the pooled mean baseline pO2 between
the two sublines showed that both the small and large groups
of AT1 tumors had significantly lower mean pO2 than the
size-matched H groups (P<.001). Oxygen breathing pro-
duced significant increase in mean pO2 in all the tumor
groups (P<.001). However, hypoxic fractions (pO2<2.5 Torr;
2.5<pO2<5 Torr; 5<pO2<10 Torr) behaved differently
between the H and AT1 tumors. Specifically, for the larger
tumors, the hypoxic fractions of all the ranges in the H tumors
(18%, 8%, and 18%) decreased dramatically to less than 5%,
whereas no distinct changes were observed in the large AT1
tumors (Figures 2 and 3).
Uniquely, FREDOM allows the oxygen dynamics at multi-
ple individual locations to be followed noninvasively and
simultaneously, specifically revealing the fate of initially
hypoxic regions. Voxels with initial pO2<10 Torr through all
the three baseline measurements were followed with respect
to respiratory challenge for both H (92 voxels) and AT1 (248
voxels) sublines (Figure 4, a and b). Figure 4a shows that
oxygen breathing produced a significant increase in mean
pO2 for these initially hypoxic regions in both the H (mean
baseline pO2=3.9F 0.4 Torr; maximum pO2 observed with
oxygen=54.7F4.6 Torr) and the AT1 (mean baseline
pO2=1.2F0.1 Torr; maximum pO2=17.9F 2.3 Torr) tumors
(P<.01). However, comparison of the median pO2 for these
voxels showed a dramatic increase in the H tumors (baseline
pO2=4.1 Torr to maximum pO2=46.2 Torr) versus only a
small increase in the corresponding regions of the AT1
tumors (baseline pO2=1.5 Torr to maximum pO2=5.3 Torr).
We also examined these hypoxic voxels grouped as having
baseline pO2<5 Torr, or in the range 5 to 10 Torr. For the
AT1 tumors, both subsets behaved equivalently and in line
with the trace shown in Figure 4a. For the H tumors, each
subset showed a significant increase, but the pO2 achieved
was significantly higher for those voxels, which started in the
5- to 10-Torr group. Moreover, Figure 4b shows that about
90% initially hypoxic regions became well oxygenated with
oxygen breathing in the H tumors, whereas>60% of the
hypoxic regions in the AT1 tumors remained. Hypoxic
regions in the groups of small and large AT1 tumors did
not behave significantly differently (P>.3).
pO2 data were also compared on the basis of differences
between individual tumors, as shown in Table 1. As with the
Table 1. Comparison of pO2 Data in Individual R3327 Dunning Prostate Rat Tumors.
Tumor Size Number Baseline (21% O2) Oxygen Challenge (100% O2)
Subline
pO2 (Torr) Hypoxic Fractions (%) pO2 (Torr) Hypoxic Fractions (%)
MeanFSE Median HF5 HF10 MeanFSE Median HF5 HF10
H Small 6 33.8F4.4 30.1F4.4 9F2 16F2 137.2F22.9* 121.1F21.2* 1F1* 3F1*
Large 6 12.7F1.1y 11.4F1.6y 31F4y 46F5y 83.1F16.2* 68.5F20.0* 7F3* 10F4*
AT1 Small 7 10.4F2.1z 7.9F2.3z 42F7z 61F7z 62.4F13.1*,z 55.4F21.0z 19F7*,z 24F9*,z
Large 6 3.5F1.2y,z 2.1F1.0y
,z 65F5y,z 83F3y,z 40.6F20.1 23.2F15.5 46F11z 59F14z
Small: <1.5 cm3; large: >3 cm3; HF5 or 10: hypoxic fraction (<5 or 10 Torr).
*P<.05 from baseline.
yP<.05 from the small group.
zP<.05 from the H tumors.
Table 2. Comparison of Hypoxic Fraction With Histology.
Tumor FREDOM Hypoxic fraction (%) Histology
Subline
HF2.5 HF5 HF10 Necrosis (%) Hypoxia Marker
Pimonidazole (%)
Vascular Density
CD31 (/mm2)
H 21F3 31F4 46F5 2F1 5F1 139F30
AT1 51F5* 65F5* 83F3* 7F1 18F4* 45F13*
HF2.5, 5 or 10: hypoxic fraction (<2.5, 5, or 10 Torr).
*P<.05 from H tumors.
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pooled data, for both the H and AT1 tumors, the large tumors
were significantly more hypoxic than the smaller tumors, and
the AT1 tumors were significantly less well oxygenated than
the size-matched H tumors (P<.05; Tables 1 and 2). With
respect to oxygen challenge, all the tumors in the H subline
and the small AT1 showed significant increases in global
mean pO2 (P<.001), whereas three of six larger AT1 tumors
did not respond to oxygen. The mean and median pO2
increased, and the HF5 or 10 decreased significantly in the
H and the small AT1 tumors with oxygen inhalation (P<.05;
Table 1). Mean pO2 of the group of six large tumors did
increase, but only reached a P<.1 level of significance.
Immunohistochemistry
AT1 tumors were significantly more hypoxic than the H
tumors of comparable size (Figure 5 and Table 2). The
positive staining for pimonidazole in the AT1 tumors was
primarily detected in tumor cells located in perinecrotic
regions and more than 100 Am away from blood vessels,
which were recognized by the anti-CD31 antibody (Figure 5,
C and D). The total number of vessels per square millimeter
was 139F30 (range 88–227) in the better-oxygenated H
tumors, which was significantly higher than for the more
hypoxic AT1 tumors (45F13/mm2, range 28–71, P<.05;
Figure 5 and Table 2). This difference in vascularity also
coincided with the greater necrotic fraction: about 7% area in
the AT1 tumors compared with only 2% in the H tumors
(Table 2).
Discussion
The anaplastic and faster-growing AT1 tumors were sig-
nificantly more hypoxic than the well-differentiated and
slower-growing H tumors from which they were originally
derived. These results are consistent with previous reports
comparing oxygenation and radiation sensitivity of the AT
and H sublines. Based on electrode polarographic pO2
measurements, the H subline was found to be considerably
less hypoxic [18]. This coincided with [31P]NMR showing
Figure 5. Distribution of pimonidazole and CD31 in representative large H and AT1 tumors (A) Well-differentiated H tumor comprising multiple glandular structures
and connective stroma. Immunostaining for hypoxia marker, pimonidazole showed few positive cells. (B) Anti-CD31 staining (brown) demonstrated relatively well-
distributed vascular endothelial cells in a consecutive 6-lm section. (C) The anaplastic AT1 tumor is composed of nonglandular structure and fewer stromal cells.
Typical distribution of hypoxia in the AT1, recognized as positive staining for pimonidazole (brown), was observed at some distance from blood vessels stained for
CD31 (D, arrow) and located adjacent to necrotic regions (N).
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greater phosphocreatine and less inorganic phosphate (Pi)
in H tumors [19]. Moreover, radiation sensitivity of AT, but
not H, tumors could be enhanced by misonidazole [20],
suggesting a lack of hypoxia in the H tumors. We have
ourselves examined AT1 tumors previously during the
development of the [19F]MRI oximetry technique [8,21].
The mean and median pO2 values reported now and
previously are remarkably similar, together with distribution
histograms and hypoxic fractions. In all cases, we have
found that larger tumors are significantly less well oxy-
genated than small tumors and, indeed, this was also
observed in other Dunning prostate R3327 tumors sublines
(MAT-Lu and HI) [9,22] and rat breast tumors [23]. Yeh
et al. [18] found no such correlation with size for either
subline based on electrode oximetry, but 31PNMR did show
metabolic hypoxiation in larger AT tumors [19]. Interlabor-
atory comparison must recognize differences in techniques
and procedures. The histology of our tumors is very similar
to that of Yeh et al. [18] and Thorndyke et al. [20], and
growth of the H tumors is comparable. However, wework with
the AT1 subline [10], as opposed to the AT, andwe find a VDT
of 5 days as opposed to 2 or 3 days [20]. In comparing our
own previous data, we have now altered our anesthesia
protocol to a baseline of air/isoflurane as opposed to 33%
oxygen in nitrous oxide with metafane [8,21]. Nonetheless,
the pO2 distributions appear very similar.
In addition to providing tumor baseline pO2, the FREDOM
technique allows the study of oxygen dynamics in response
to interventions (e.g., respiratory challenge). Our results
show that oxygen breathing produced significant increase
in mean pO2 in all the H tumors and the small AT1 tumors,
whereas the change was only borderline significant in the
larger AT1 tumors (Table 1). Most interestingly, the initially
hypoxic regions in the H tumors responded significantly to
become well oxygenated with oxygen challenge, whereas no
distinct reduction in hypoxic fractions was observed in the
large AT1 tumors (Table 1 and Figure 4, a and b). The AT1
tumor data coincide with our previous observations in this
subline [21].
There is increasing evidence that tumor malignant pro-
gression may be associated with a hypoxic microenvi-
ronment [5,6,24]. Several recent clinical studies have
demonstrated a positive relationship between the presence
of hypoxia and poor outcome associated with malignant
progression and metastasis in several cancers (e.g., ad-
vanced squamous cell carcinoma of the cervix [3,25,26],
and sarcomas and carcinomas from head, neck, and soft
tissue [27]). Studies of breast cancer have not all been
consistent. For example, early work by Vaupel et al. [28]
showed no correlation between grade or stage and pO2
using the Eppendorf Histograph. By contrast, a recent report
from Hohenberger et al. [29] indicated that mean pO2 and
hypoxic fraction in breast tumors were associated with both
grade and stage. The results of Ho¨ckel et al. [3] in advanced
cervical cancer patients showed a lack of correlation
between tumor oxygenation and differentiation or stage,
but a significantly positive correlation of tumor oxygenation
and malignant progression. In an animal model, Thews et al.
[30] reported that a higher differentiated rhabdomyosarcoma
subline, F1, of the BA-HAN-1 was less well oxygenated than
the undifferentiated G8 subline. Although the results of
Thews et al. show the opposite trend to the observations
we report here, it is important to note that the F1 and G8
tumors grow relatively rapidly. In our studies, the higher
differentiated tumors grow much more slowly. Several other
studies have shown evidence that tumor malignant progres-
sion (e.g., local invasion, destructive growth and metastasis)
may be associated with hypoxic microenvironment in both
experimental models [5,24,31,32] and the clinic [25,26,33]. A
recent study by Movsas et al. [34] using the Eppendorf
Histograph showed that increasing levels of hypoxia were
related to increasing clinical stage of human prostate carci-
nomas, but trends with respect to grade did not reach
significance. Eble et al. [35] found that the moderately well-
differentiated Dunning rat prostate HI subline was better
oxygenated than the anaplastic AT1 subline, and Yeh et al.
[18] found that the well-differentiated H subline was better
oxygenated than the anaplastic AT. Our previous study of
two other Dunning prostate R3327 rat tumor sublines
showed that the poorly differentiated and faster-growing
(VDT=2.7 days) and metastatic MAT-Lu tumors were less
well oxygenated than the moderately differentiated and
slower-growing (VDT=9 days) HI tumors. Similar to the
results here, breathing hyperoxic gas (oxygen or carbogen)
significantly increased the oxygenation and reduced the
hypoxic fraction in the HI tumors, but to a much lesser extent
in the metastatic MAT-Lu tumors [9]. This would tend to
support the hypothesis that tumor hypoxia is associated with
parameters such as increased growth rate and level of
differentiation (grade). As in our previous studies [9,22,23]
of various tumor types, tumor size, which is a major compo-
nent of tumor staging, showed a strongly inverse relationship
to oxygenation.
Many experimental and clinical studies have demonstra-
ted that reoxygenation of hypoxic tumor cells contributes to
improved radiation sensitivity for tumor therapy [36,37].
Whether initially hypoxic regions of a tumor can be modified
to become better oxygenated has long been considered a
key indicator for outcome of irradiation. Examining the
initially hypoxic regions (pO2<10 Torr) showed that more
than 90% of the hypoxic regions in the H tumors became
better oxygenated in response to oxygen breathing. In
contrast, about 60% of such regions from the AT1 tumors
remained unchanged (Figure 4b). Thus, one would expect
that radiosensitivity of the H tumors might be significantly
improved with pretreatment oxygen breathing, whereas
beneficial effect in the AT1 tumors would be less. In fact,
measurements in HI tumors with respect to our recent
experimental radiotherapy have validated the hypothesis.
We found that oxygen breathing before and during a 30-Gy
single-dose irradiation significantly enhanced the radiosen-
sitivity by prolonging the tumor growth delay in large HI
tumors [38]. Intriguingly, breathing oxygen had no benefit in
small HI tumors coinciding with a very small baseline
hypoxic fraction. By analogy, one would expect that patients
with hypoxic tumors like the large H and HI would show
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enhanced local control by irradiation in combination with
oxygen breathing. Actually, recent clinical data have shown
promising results in advanced head and neck cancers
accomplished by accelerated radiotherapy with the carbo-
gen and nicotinamide (ARCON) schedule. The phase II trial
demonstrated that the ARCON has significantly improved 3-
year local control rates to 80% for larynx, 69% for hypo-
pharynx, 88% for oropharynx cancers [39], and those
patients with hypoxic tumors received the greatest benefit
from the ARCON paradigm [33].
Comparison of Figure 4, a and b shows that the mean pO2
in the initially hypoxic regions from both the H and the AT1
tumors continued to increase during the course of 40-minute
oxygen breathing, whereas the corresponding hypoxic frac-
tion in both sublines dropped to a minimum value within
24 minutes and then remained stable. This discrepancy
suggests that hypoxic regions may be divided into two
categories: those that are modulated by oxygen within
24 minutes and continue to show increase at later times,
versus those that are unresponsive. This information could
be valuable for guiding and planning radiotherapy. In our
previous studies of the Dunning prostate rat tumors, we
found that oxygen or carbogen breathing produced a similar
effect on tumor oxygenation across all the sublines MAT-Lu,
AT1, and HI [8,9,21,22,40]. Our irradiation study validated
that oxygen breathing significantly improved radiosensitivity
in initially hypoxic large HI tumors [38].
HFB has many strengths as a reporter molecule: MR
interrogation is nondestructive, and HFB exhibits remarkably
low toxicity and is readily available. From an MR perspective,
HFB is ideal, having a single resonance, high sensitivity to
pO2, and minimal sensitivity to temperature [41]. The
high vapor pressure produces a short biological half-life
(T1/2f600 minutes) [40], but there is little macroscopic
redistribution over a period of 2.5 hours allowing effective
investigations of acute interventions [41]. The Hamilton
syringe with a custom-made fine sharp needle (32 gauge)
was designed to minimize tissue damage. Our current data,
as well as our previous observations, have demonstrated the
stability of local pO2 measurements under baseline condi-
tions. FREDOM oximetry has been validated by various
techniques in previous studies (e.g., similar baseline pO2
distribution in the AT1 tumors acquired by Eppendorf Histo-
graph [21] and comparable oxygen dynamics with oxygen or
carbogen challenge observed in HI tumors using the fiber
optic OxyLite [22] or oxygen electrodes [9]).
Tumor oxygenation may be investigated at many levels,
ranging from induced gene expression to cellular microscopy
and macroscopic techniques. Ultimately, correlation with
outcome is relevant to clinical application, as has been
demonstrated for measurements using the Eppendorf Histo-
graph [3,26,27] and, most recently, pimonidazole binding
[33]. We have previously shown that pO2 measurements
using FREDOM were similar to the Histograph and now we
show that hypoxic fractions are commensurate with pimoni-
dazole binding. The anaplastic and faster-growing AT1
tumors had significantly higher pimonidazole binding (18%)
than the well-differentiated and slower-growing H tumors
(5%, P<.05), consistent with the FREDOM measurements.
However, as shown in Table 2, the hypoxic fractions
HF2.5,5,10 measured by FREDOM for the large AT1 tumors
were far greater than the extent of pimonidazole binding.
Others have also reported such discrepancies using Histo-
graph or OxyLite [12,42]. Histograph assessment of oxygen-
ation does not differentiate hypoxic live tissues from necrotic
regions, leading to overestimation of tumor hypoxia [43,44].
However, in our tumors, the level of necrosis is relatively
small and would not account for the disparity. It has also been
suggested that diffusion may limit the distribution of biore-
ductive hypoxiamarkers, leading to underestimation of tumor
hypoxia [45] and, in addition, nitroimidazole binding may be
influenced by levels of both nitroreductase and thiol [46].
Furthermore, a pO2 threshold value for hypoxic marker bind-
ing is not clearly defined in vivo. There may also be differ-
ences in sensitivity to chronic versus acute hypoxia and the
time required for efficient pimonidazole labeling. Bennewith
et al. [47] have now shown significantly greater pimonidazole
binding when assessed following 96 hours of continuous oral
availability, as opposed to a single intravenous or intraper-
itoneal dose followed by tissue harvest after 6 hours. Here,
we followed the manufacturer’s recommendations of a 90-
minute delay between intravenous administration and sacri-
fice. Despite the lack of absolute correspondence, a general
positive correlation in assessments of tumor hypoxia has
been reported between Histograph or OxyLite and pimonida-
zole binding by others [12,44], and now by us here.
Tumor hypoxia results, in part, from inadequate blood
vessel development and solid tumors appear not to grow
beyond a critical size of f1 mm3 without evoking angio-
genesis [48]. Figure 5 shows a typical case of insufficient
blood vessels in a region of an AT1 tumor, which results in
hypoxia and eventually necrosis with increased distance
away from the vessels. The anti-CD31 staining for vascular
endothelial cells showed that the more hypoxic AT1 tumors
had lower vascular density than the better-oxygenated H
tumors (Table 2). This result is in agreement with other
reports in various animal or human tumors indicating
greater hypoxia at reduced vascular density [11,44]. How-
ever, some studies have shown the opposite trend [17,49],
may be because hypoxia stimulates angiogenesis, generat-
ing greater neovasculature. Here, we have applied histo-
logical approaches to assess hypoxia in relation to vascular
density. Others have examined additional pertinent param-
eters including vascular perfusion (e.g., using distribution of
the Hoechst 33342 dye) [14,38] and even dynamic changes
by applying pairs of distinct hypoxia markers (CCI-103F and
pimonidazole) sequentially before and after an intervention
to reveal dynamic response (pulse chase double labeling)
[14]. Specifically, they were able to detect changes in tumor
hypoxia following interventions designed to modulate hypo-
xia such as breathing hyperoxic gas and hydralazine.
Ultimately, dynamic studies will be of great importance,
and the availability and correlation of many diverse techni-
ques revealing tissue and cellular properties on various
scales from whole tumor to microscopic resolution will
be pertinent.
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The FREDOM approach to tumor oximetry has the great
advantage of facilitating noninvasive assessment of changes
in pO2 in response to interventions, as shown here for
breathing hyperoxic gases and previously for vasoactive
agents, such as hydralazine [50], or vascular targeting
agents [51]. The method is inherently quantitative, but it
does require introduction of small quantities (f50 Al) of the
reporter molecule, HFB. Another drawback for potential
clinical application is the current lack of an [19F]NMR channel
on most clinical MRI scanners. Currently, we estimate that at
least 20 research instruments in the world have a clinical
[19F]EPI capability and this will increase dramatically with the
popularity of high field systems (e.g., 3 T). Our own institution
is installing its first clinical [19F]MRI capability in spring 2003
and we envisage clinical application of the FREDOM in the
near future. We are currently investigating Investigational
New Drug approval for HFB.
We and others are also searching for alternative non-
invasive approaches. Near-infrared reveals changes in vas-
cular oxygenation with high time resolution, but currently little
spatial discrimination [52]. BOLD (Blood Oxygen Level–
Dependent) contrast [1H]MRI provides spatial resolution
and is sensitive to changes in vascular oxygenation, but also
is sensitive to changes in tumor blood flow and tumor blood
volume (FLOOD) [53]. Moreover, correlations between
changes in signal intensity and direct measures of pO2 have
shown a qualitative relationship, but poor indication of abso-
lute pO2 [54,55]. In some cases, correlation has been shown
between pO2 and dynamic contrast-enhanced (DCE)
[1H]MRI [56,57], but although DCE can reveal changes in
vascular flow and permeability, it must be recognized that
tissue pO2 represents a balance between oxygen delivery
and consumption, and thus, such correlations are unlikely to
be valid across diverse tumor types.
In conclusion, we have demonstrated that in comparison
with the H tumor, the anaplastic and faster-growing AT1
subline of the Dunning R3327 tumor is significantly more
hypoxic. Comparable data using histological markers of
hypoxia and vascular endothelium further validate the
assessment of tumor oxygenation by FREDOM. We believe
this approach can provide valuable insight into tumor phys-
iology and response to interventions, assisting in the devel-
opment of novel therapeutic strategies. Ultimately, FREDOM
should have application in the clinical setting.
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